Skin auto-fluorescence
PreclinicalBiologic
Skin auto-fluorescence is one of 8 biologic programs targeting Myocardial fibrosis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Myocardial Fibrosis
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaApproved
Invokana
WWim Janssens
Approved
Esbriet
LLegacy Health System
Approved
Aldactone
PfizerPhase 3
Torasemide
Boehringer IngelheimApproved
Dihydralazine
UUniversity Medical Center Goettingen
Phase 3
Henagliflozin
TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Preclinical
Skin auto-fluorescence
HHospices Civils de Lyon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Skin auto-fluorescence. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- HHospices Civils de Lyon